Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANA773 tosylate with ribavirin in chronic hepatitis C
NL-OMON35795Phase 2Withdrawn
- Sponsor
- Anadys Pharmaceuticals
- Start
- Apr 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hepatitis C virus infection comparing ANA773 tosylate + ribavirin with Standard of care: pegylated interferon-alpha + ribavirin (2 arms). Primary endpoints: Hepatitis C viral load, Adverse events and 4 more. Planned start Apr 2011; status: withdrawn.
02
Drugs
RG-7795ribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON35795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35795.